Payment overview · 2025
General Payments
$174.13
11 reported records · 7 companies
Healthcare provider profile · identity verified
Marc Sciarra, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PINEHURST, NC · NPI 1760894083
Verified facts
What the public records show
CMS Open Payments records show Marc Sciarra, D.O. received $174.13 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rexulti, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.92 | 31.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.59 | 26.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.59 | 10.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.13 | 9.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.57 | 8.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.51 | 7.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.82 | 6.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $174.13 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $45.59 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.82 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 131 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 134 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
134 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 719 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 696 | 198 |
| Gabapentin | Gabapentin | 455 | 118 |
| Omeprazole | Omeprazole | 381 | 99 |
| Furosemide | Furosemide | 373 | 102 |
| Losartan Potassium | Losartan Potassium | 331 | 70 |
| Prednisone | Prednisone | 329 | 193 |
| Hydrochlorothiazide | Hydrochlorothiazide | 326 | 104 |
| Doxycycline Hyclate | Doxycycline Hyclate | 301 | 172 |
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 65 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 285 | 40 |
| Alprazolam | Alprazolam | 277 | 60 |
| Lisinopril | Lisinopril | 265 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 71 |
| Metformin Hcl | Metformin Hcl | 239 | 69 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 233 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 59 |
| Potassium Chloride | Potassium Chloride | 209 | 54 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 207 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 200 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 176 | 32 |
| Simvastatin | Simvastatin | 175 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 57 |
| Trazodone Hcl | Trazodone Hcl | 172 | 48 |
| Glipizide | Glipizide | 167 | 51 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 164 | 127 |
| Metoprolol Tartrate | Metoprolol Tartrate | 157 | 42 |
| Chlorthalidone | Chlorthalidone | 154 | 47 |
| Atenolol | Atenolol | 136 | 32 |
| Farxiga | Dapagliflozin Propanediol | 134 | 29 |
| Allopurinol | Allopurinol | 133 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 133 | 24 |
| Eliquis | Apixaban | 131 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 117 | 61 |
| Carvedilol | Carvedilol | 113 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 65 |
| Spironolactone | Spironolactone | 112 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 100 | 22 |
| Tramadol Hcl | Tramadol Hcl | 99 | 33 |
| Meloxicam | Meloxicam | 97 | 28 |
| Mirtazapine | Mirtazapine | 97 | 21 |
| Ozempic | Semaglutide | 97 | 20 |
| Pregabalin | Pregabalin | 87 | 13 |
| Sertraline Hcl | Sertraline Hcl | 87 | 28 |
| Clonidine Hcl | Clonidine Hcl | 79 | 11 |
| Montelukast Sodium | Montelukast Sodium | 78 | 15 |
| Januvia | Sitagliptin Phosphate | 74 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 73 | 44 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 72 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 15 |
| Fluconazole | Fluconazole | 67 | 41 |
| Benazepril Hcl | Benazepril Hcl | 65 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 63 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 15 |
| Jardiance | Empagliflozin | 59 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | 15 |
| Clonidine | Clonidine | 57 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | suppressed |
| Baclofen | Baclofen | 55 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 55 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 11 |
| Azithromycin | Azithromycin | 50 | 40 |
| Rybelsus | Semaglutide | 50 | 11 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Ezetimibe | Ezetimibe | 49 | suppressed |
| Celecoxib | Celecoxib | 47 | 18 |
| Donepezil Hcl | Donepezil Hcl | 45 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 14 |
| Lovastatin | Lovastatin | 44 | 13 |
| Methylprednisolone | Methylprednisolone | 43 | 35 |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Topiramate | Topiramate | 43 | 12 |
| Finasteride | Finasteride | 42 | 13 |
| Famotidine | Famotidine | 41 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 12 |
| Sucralfate | Sucralfate | 41 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 39 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 12 |
| Linzess | Linaclotide | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | 11 |
| Ondansetron Odt | Ondansetron | 32 | 17 |
| Cephalexin | Cephalexin | 31 | 19 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 13 |
| Colchicine | Colchicine | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Haloperidol | Haloperidol | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | 11 |
| Ketoconazole | Ketoconazole | 25 | 14 |
| Ramipril | Ramipril | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 15 |
| Naproxen | Naproxen | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 16 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | 11 |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $174.13 · 11 records | Novo Nordisk Inc | ELIQUIS, FARXIGA, JARDIANCE, NEXLETOL, NURTEC ODT, Ozempic, REXULTI, Rybelsus, VOQUEZNA, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error